dc.contributor.author | Malme, Kristian Nødtvedt | |
dc.contributor.author | Ulstein, Kjersti Anne | |
dc.contributor.author | Finbråten, Ane-Kristine | |
dc.contributor.author | Wüsthoff, Linda Elise | |
dc.contributor.author | Kielland, Knut Boe | |
dc.contributor.author | Hauge, Joakim | |
dc.contributor.author | Dalgard, Olav | |
dc.contributor.author | Midgard, Håvard | |
dc.date.accessioned | 2023-10-11T13:17:08Z | |
dc.date.available | 2023-10-11T13:17:08Z | |
dc.date.created | 2023-05-31T09:40:06Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | International journal of drug policy. 2023 Jun:116:104044. | en_US |
dc.identifier.issn | 0955-3959 | |
dc.identifier.uri | https://hdl.handle.net/11250/3095838 | |
dc.description.abstract | Background
Improving HCV treatment uptake among people who inject drugs (PWID) is crucial to achieving the WHO elimination targets. The aims were to evaluate HCV treatment uptake and HCV RNA prevalence in a large cohort of PWID in Norway.
Methods
Registry-based observational study where all users of the City of Oslo's low-threshold social and health services for PWID between 2010–2016 ( n = 5330) were linked to HCV notifications (1990–2019) and dispensions of HCV treatment, opioid agonist treatment (OAT) and benzodiazepines (2004–2019). Cases were weighted to account for spontaneous HCV clearance. Treatment rates were calculated using person-time of observation, and factors associated with treatment uptake were analysed using logistic regression. HCV RNA prevalence was estimated among individuals alive by the end of 2019.
Results
Among 2436 participants with chronic HCV infection (mean age 46.8 years, 30.7% female, 73.3% OAT), 1118 (45.9%) had received HCV treatment between 2010–2019 (88.7% DAA-based). Treatment rates increased from 1.4/100 PY (95% CI 1.1–1.8) in the pre-DAA period (2010–2013) to 3.5/100 PY (95% CI 3.0–4.0) in the early DAA period (2014–2016; fibrosis restrictions) and 18.4/100 PY (95% CI 17.2–19.7) in the late DAA period (2017–2019; no restrictions). Treatment rates for 2018 and 2019 exceeded a previously modelled elimination threshold of 50/1000 PWID. Treatment uptake was less likely among women (aOR 0.74; 95% CI 0.62–0.89) and those aged 40–49 years (aOR 0.74; 95% CI 0.56–0.97), and more likely among participants with current OAT (aOR 1.21; 95% CI 1.01–1.45). The estimated HCV RNA prevalence by the end of 2019 was 23.6% (95% CI 22.3–24.9).
Conclusion
Although HCV treatment uptake among PWID increased, strategies to improve treatment among women and individuals not engaged in OAT should be addressed. | en_US |
dc.description.sponsorship | This research received funding from the following sources. KM receives research grants from the South-Eastern Norway Regional Health Authority , grant number: 2020011 .
The funding sponsor has not been involved in study design, collection of data, analysis/interpretation of data, in the writing of the article, or in the decision to submit the article for publication. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.subject | Direct-acting antivirals; | en_US |
dc.subject | Hepatitis C virus elimination; | en_US |
dc.subject | Hepatitis C virus treatment; | en_US |
dc.subject | People who inject drugs. | en_US |
dc.title | Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_US |
dc.source.volume | 116 | en_US |
dc.source.journal | International journal of drug policy | en_US |
dc.identifier.doi | 10.1016/j.drugpo.2023.104044 | |
dc.identifier.cristin | 2150353 | |
dc.relation.project | [South-Eastern Norway Regional Health Authority]: [2020011] | en_US |
dc.source.articlenumber | 104044 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |